Infinity Provides Company Update And Reports Third Quarter 2015 Financial Results - Infinity Receives FDA Fast Track Designation for Duvelisib for Follicular Lymphoma in Patients Who Have Received at Least Two Prior Therapies -- DUO™ Study On-Track for Enrollment Completion By Year End -- Three Clinical Studies with Duvelisib Expected to Initiate by Year End -- Preclinical Data and Data from Investigator-Sponsored Studies of Duvelisib to Be Presented at ASH -

, Nov. 5, 2015 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2015 financial results and ongoing progress with its pipeline, including duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. Infinity also announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the investigation of duvelisib for the treatment of patients with follicular lymphoma (FL) who have received at least two prior therapies. Earlier this year, Infinity received Fast Track designation for the...